Cadence Sues Sandoz Over Generic Ofirmev Plans

Law360, New York (February 5, 2013, 1:38 PM EST) -- Cadence Pharmaceuticals Inc. sued Sandoz Inc. in California federal court Monday over Sandoz's plan to make a generic version of the injectable pain reliever Ofirmev, alleging the generic would infringe patents covering the branded drug.

Cadence said Sandoz has submitted an abbreviated new drug application with the U.S. Food and Drug Administration, seeking approval to manufacture and sell a generic version of Ofirmev, which is an injectable form of acetaminophen and is used to manage mild to moderate pain. If allowed to pursue its generic, Sandoz...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.